{"title":"评估 Triphala 对高脂饮食喂养大鼠的抗高血脂作用:两种组合的研究。","authors":"Suman Rana, Princy Louis Palatty, Ruby Benson, Benson Mathai Kochikuzhyil, Manjeshwar Shrinath Baliga","doi":"10.4103/ayu.AYU_74_19","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Hyperlipidemia is one of the major risk factors for coronary heart disease and stroke. <i>Triphala</i>, a polyherbal Ayurvedic formulation made from dried fruits of <i>Haritaki</i> (<i>Terminalia chebula</i> Retz.), <i>Bibhitaki</i> (<i>Terminalia bellirica</i> Roxb.), and <i>Amalaki</i> (<i>Phyllanthus emblica</i> Gaertn.) has been suggested to be useful in mitigating hyperlipidemia. In the Ayurveda texts, depending on the patient's condition and body type, <i>Triphala</i> is formulated and used in one of the two combination (1:1:1 and 1:2:4 of individual constituents) forms.</p><p><strong>Aims: </strong>The present study aimed at evaluating the efficacy of two combinations (1:1:1 and 1:2:4 of individual constituents) of <i>Triphala</i> against high fat diet induced-hyperlipidemia in rats.</p><p><strong>Materials and method: </strong>Hyperlipidemia was induced in Spraque-Dawley albino rats by feeding them with high fat diet. The animals were concomitantly administered with graded dose of one of the two combination (combination of <i>Haritaki</i>, <i>Bibhitaki</i>, and <i>Amalaki</i> in ratio of 1:1:1 or 1:2:4, respectively) of <i>Triphala</i> (250, 500, or 1000 mg/kg body wt.) or atorvastatin. The animals were sacrificed on day 22 and serum was processed for lipid profile and the liver for lipid peroxidation. The statistical analysis was performed by the mean analysis of variance followed by Dunnet's test.</p><p><strong>Results: </strong>The results indicated that when compared to placebo group, levels of serum total cholesterol, and triglyceride were significantly lower, while high-density lipoprotein cholesterol increased in both the <i>Triphala</i> combination and atorvastatin groups. Of the two groups of <i>Triphala</i>, the formulation having 1:2:4 ratio was better than the 1:1:1. The group having highest drug dose (1000 mg/kg body wt.) of 1:2:4 formulation was better than atorvastatin in rectifying high fat diet-induced dyslipidemia and the atherogenic index was equal to that of atorvastatin.</p><p><strong>Conclusions: </strong>The results of the study indicate that of the two <i>Triphala</i> formulations, the 1:2:4 ratio was better than the 1:1:1 ratio for anti-hyper-lipidemic effects.</p>","PeriodicalId":502094,"journal":{"name":"Ayu","volume":"43 3","pages":"98-104"},"PeriodicalIF":0.0000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710234/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the anti-hyperlipidemic effects of <i>Triphala</i> in high fat diet fed rats: Studies with two combinations.\",\"authors\":\"Suman Rana, Princy Louis Palatty, Ruby Benson, Benson Mathai Kochikuzhyil, Manjeshwar Shrinath Baliga\",\"doi\":\"10.4103/ayu.AYU_74_19\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Hyperlipidemia is one of the major risk factors for coronary heart disease and stroke. <i>Triphala</i>, a polyherbal Ayurvedic formulation made from dried fruits of <i>Haritaki</i> (<i>Terminalia chebula</i> Retz.), <i>Bibhitaki</i> (<i>Terminalia bellirica</i> Roxb.), and <i>Amalaki</i> (<i>Phyllanthus emblica</i> Gaertn.) has been suggested to be useful in mitigating hyperlipidemia. In the Ayurveda texts, depending on the patient's condition and body type, <i>Triphala</i> is formulated and used in one of the two combination (1:1:1 and 1:2:4 of individual constituents) forms.</p><p><strong>Aims: </strong>The present study aimed at evaluating the efficacy of two combinations (1:1:1 and 1:2:4 of individual constituents) of <i>Triphala</i> against high fat diet induced-hyperlipidemia in rats.</p><p><strong>Materials and method: </strong>Hyperlipidemia was induced in Spraque-Dawley albino rats by feeding them with high fat diet. The animals were concomitantly administered with graded dose of one of the two combination (combination of <i>Haritaki</i>, <i>Bibhitaki</i>, and <i>Amalaki</i> in ratio of 1:1:1 or 1:2:4, respectively) of <i>Triphala</i> (250, 500, or 1000 mg/kg body wt.) or atorvastatin. The animals were sacrificed on day 22 and serum was processed for lipid profile and the liver for lipid peroxidation. The statistical analysis was performed by the mean analysis of variance followed by Dunnet's test.</p><p><strong>Results: </strong>The results indicated that when compared to placebo group, levels of serum total cholesterol, and triglyceride were significantly lower, while high-density lipoprotein cholesterol increased in both the <i>Triphala</i> combination and atorvastatin groups. Of the two groups of <i>Triphala</i>, the formulation having 1:2:4 ratio was better than the 1:1:1. The group having highest drug dose (1000 mg/kg body wt.) of 1:2:4 formulation was better than atorvastatin in rectifying high fat diet-induced dyslipidemia and the atherogenic index was equal to that of atorvastatin.</p><p><strong>Conclusions: </strong>The results of the study indicate that of the two <i>Triphala</i> formulations, the 1:2:4 ratio was better than the 1:1:1 ratio for anti-hyper-lipidemic effects.</p>\",\"PeriodicalId\":502094,\"journal\":{\"name\":\"Ayu\",\"volume\":\"43 3\",\"pages\":\"98-104\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10710234/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ayu\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/ayu.AYU_74_19\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/10/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ayu","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ayu.AYU_74_19","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Evaluation of the anti-hyperlipidemic effects of Triphala in high fat diet fed rats: Studies with two combinations.
Background: Hyperlipidemia is one of the major risk factors for coronary heart disease and stroke. Triphala, a polyherbal Ayurvedic formulation made from dried fruits of Haritaki (Terminalia chebula Retz.), Bibhitaki (Terminalia bellirica Roxb.), and Amalaki (Phyllanthus emblica Gaertn.) has been suggested to be useful in mitigating hyperlipidemia. In the Ayurveda texts, depending on the patient's condition and body type, Triphala is formulated and used in one of the two combination (1:1:1 and 1:2:4 of individual constituents) forms.
Aims: The present study aimed at evaluating the efficacy of two combinations (1:1:1 and 1:2:4 of individual constituents) of Triphala against high fat diet induced-hyperlipidemia in rats.
Materials and method: Hyperlipidemia was induced in Spraque-Dawley albino rats by feeding them with high fat diet. The animals were concomitantly administered with graded dose of one of the two combination (combination of Haritaki, Bibhitaki, and Amalaki in ratio of 1:1:1 or 1:2:4, respectively) of Triphala (250, 500, or 1000 mg/kg body wt.) or atorvastatin. The animals were sacrificed on day 22 and serum was processed for lipid profile and the liver for lipid peroxidation. The statistical analysis was performed by the mean analysis of variance followed by Dunnet's test.
Results: The results indicated that when compared to placebo group, levels of serum total cholesterol, and triglyceride were significantly lower, while high-density lipoprotein cholesterol increased in both the Triphala combination and atorvastatin groups. Of the two groups of Triphala, the formulation having 1:2:4 ratio was better than the 1:1:1. The group having highest drug dose (1000 mg/kg body wt.) of 1:2:4 formulation was better than atorvastatin in rectifying high fat diet-induced dyslipidemia and the atherogenic index was equal to that of atorvastatin.
Conclusions: The results of the study indicate that of the two Triphala formulations, the 1:2:4 ratio was better than the 1:1:1 ratio for anti-hyper-lipidemic effects.